{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:58:20Z","timestamp":1790351900910,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["318346496 \\u2013 SFB 1292"],"award-info":[{"award-number":["318346496 \\u2013 SFB 1292"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TP09"],"award-info":[{"award-number":["TP09"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.pharmthera.2024.108764","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T11:24:46Z","timestamp":1733138686000},"page":"108764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["EGFL7: An emerging biomarker with great therapeutic potential"],"prefix":"10.1016","volume":"266","author":[{"given":"Carina","family":"Fabian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukrit","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko H.H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2024.108764_bb0005","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1161\/CIRCULATIONAHA.109.927715","article-title":"Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia\/reoxygenation injury in human coronary artery endothelial cells","volume":"122","author":"Badiwala","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00018-023-04685-z","article-title":"EGFL7 loss correlates with increased VEGF-D expression, upregulating hippocampal adult neurogenesis and improving spatial learning and memory","volume":"80","author":"Barth","year":"2023","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0015","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.4161\/cc.9.7.11091","article-title":"EGFL7: A new player in homeostasis of the nervous system","volume":"9","author":"Bicker","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0020","doi-asserted-by":"crossref","first-page":"15922","DOI":"10.1038\/ncomms15922","article-title":"Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception","volume":"8","author":"Bicker","year":"2017","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108764_bb0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1158\/1078-0432.CCR-19-2479","article-title":"EGFL7 antagonizes NOTCH signaling and represents a novel therapeutic target in acute myeloid leukemia","volume":"26","author":"Bill","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9440(10)62972-0","article-title":"EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury","volume":"167","author":"Campagnolo","year":"2005","journal-title":"The American Journal of Pathology"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108764_bb0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nn.2268","article-title":"Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke","volume":"12","author":"Carlen","year":"2009","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.placenta.2003.10.004","article-title":"Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation","volume":"25","author":"Charnock-Jones","year":"2004","journal-title":"Placenta"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.devcel.2013.03.003","article-title":"CASZ1 promotes vascular assembly and morphogenesis through the direct regulation of an EGFL7\/RhoA-mediated pathway","volume":"25","author":"Charpentier","year":"2013","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0055","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1038\/s41467-024-50389-8","article-title":"Epidermal growth factor-like domain 7 drives brain lymphatic endothelial cell development through integrin alphavbeta3","volume":"15","author":"Chen","year":"2024","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0060","first-page":"35","article-title":"MicroRNA-126: A new and promising player in lung cancer","volume":"21","author":"Chen","year":"2021","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jcp.24684","article-title":"EGFL7 is expressed in bone microenvironment and promotes angiogenesis via ERK, STAT3, and integrin signaling cascades","volume":"230","author":"Chim","year":"2015","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0075","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-11-1301","article-title":"Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation","volume":"71","author":"Delfortrie","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lfs.2016.05.041","article-title":"Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression","volume":"157","author":"Deng","year":"2016","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-023-00417-6","article-title":"Pre-eclampsia","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Nature Reviews. Disease Primers"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108764_bb0090","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41583-023-00709-6","article-title":"Roles and regulation of microglia activity in multiple sclerosis: Insights from animal models","volume":"24","author":"Dist\u00e9fano-Gagn\u00e9","year":"2023","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0014-5793(00)02140-2","article-title":"EMI, a novel cysteine-rich domain of EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in multimerization","volume":"484","author":"Doliana","year":"2000","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0100","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1074\/jbc.M011591200","article-title":"Isolation and characterization of EMILIN-2, a new component of the growing EMILINs family and a member of the EMI domain-containing superfamily","volume":"276","author":"Doliana","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0105","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708420","article-title":"EGFL7 enhances surface expression of integrin alpha(5)beta(1) to promote angiogenesis in malignant brain tumors","volume":"10","author":"Dudvarski Stankovic","year":"2018","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2040-2384-2-4","article-title":"A role for Egfl7 during endothelial organization in the embryoid body model system","volume":"2","author":"Durrans","year":"2010","journal-title":"Journal of Angiogenesis Research"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5301\/JBM.2013.10568","article-title":"The expression of Egfl7 in human normal tissues and epithelial tumors","volume":"28","author":"Fan","year":"2013","journal-title":"The International Journal of Biological Markers"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.omtn.2019.05.006","article-title":"RNA aptamers targeting integrin alpha5beta1 as probes for Cyto- and Histofluorescence in glioblastoma","volume":"17","author":"Fechter","year":"2019","journal-title":"Molecular Therapy--Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.devcel.2008.07.008","article-title":"miR-126 regulates angiogenic signaling and vascular integrity","volume":"15","author":"Fish","year":"2008","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/dvdy.20063","article-title":"Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells","volume":"230","author":"Fitch","year":"2004","journal-title":"Developmental Dynamics"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0135","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1158\/0008-5472.CAN-15-0988","article-title":"Glioblastomas require integrin alphavbeta3\/PAK4 signaling to escape senescence","volume":"75","author":"Franovic","year":"2015","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108764_bb0140","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0145","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: Genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0150","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1634\/theoncologist.2016-0133erratum","article-title":"Randomized phase II trial of Parsatuzumab (anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal Cancer","volume":"22","author":"Garcia-Carbonero","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0160","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/sj.jcbfm.9600408","article-title":"Vascular response to hypoxic preconditioning in the immature brain","volume":"27","author":"Gustavsson","year":"2007","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0165","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(16)30962-X","article-title":"Stroke","volume":"389","author":"Hankey","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0170","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41598-017-02538-x","article-title":"Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab","volume":"7","author":"Hansen","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0175","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/bjc.2013.448","article-title":"MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial","volume":"109","author":"Hansen","year":"2013","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0180","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1535-7163.MCT-14-0131","article-title":"Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer","volume":"13","author":"Hansen","year":"2014","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030563","article-title":"Immunotherapy: Review of the existing evidence and challenges in breast Cancer","volume":"15","author":"Hu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108764_bb0190","first-page":"1077","article-title":"VE-statin\/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro","volume":"7","author":"Huang","year":"2014","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0195","first-page":"1022","article-title":"VE-statin\/Egfl7 expression in malignant glioma and its relevant molecular network","volume":"7","author":"Huang","year":"2014","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108764_bb0200","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00432-010-0832-9","article-title":"Expression and clinical significance of EGFL7 in malignant glioma","volume":"136","author":"Huang","year":"2010","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0205","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1172\/JCI67892","article-title":"Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy","volume":"123","author":"Johnson","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0210","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-014-1372-1","article-title":"Perivascular microglia promote blood vessel disintegration in the ischemic penumbra","volume":"129","author":"Jolivel","year":"2015","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0215","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10147-021-01888-x","article-title":"EGFL7 as a novel therapeutic candidate regulates cell invasion and anoikis in colorectal cancer through PI3K\/AKT signaling pathway","volume":"26","author":"Juan","year":"2021","journal-title":"International Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108764_bib437","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/jcb.10413","article-title":"Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell","volume":"88","author":"Kagan","year":"2003","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0220","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41573-023-00704-7","article-title":"Amplifying gene expression with RNA-targeted therapeutics","volume":"22","author":"Khorkova","year":"2023","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0225","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1242\/dev.029736","article-title":"Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126","volume":"135","author":"Kuhnert","year":"2008","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.mod.2014.04.001","article-title":"Novel expression of EGFL7 in placental trophoblast and endothelial cells and its implication in preeclampsia","volume":"133","author":"Lacko","year":"2014","journal-title":"Mechanisms of Development"},{"issue":"13","key":"10.1016\/j.pharmthera.2024.108764_bib436","first-page":"2469","article-title":"Altered feto-placental vascularization, feto-placental malperfusion and fetal growth restriction in mice with Egfl7 loss of function","volume":"144","author":"Lacko","year":"2017","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0235","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41467-018-03186-z","article-title":"EGFL7 reduces CNS inflammation in mouse","volume":"9","author":"Larochelle","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012156","article-title":"VE-statin\/egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of erg and GATA-2","volume":"5","author":"Le Bras","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0245","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/emboj.2008.103","article-title":"VE-statin\/egfl7 regulates vascular elastogenesis by interacting with lysyl oxidases","volume":"27","author":"Lelievre","year":"2008","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0250","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: Progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0255","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0260","article-title":"Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells","volume":"9","author":"Luo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0265","first-page":"1236","article-title":"Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma","volume":"7","author":"Luo","year":"2015","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0270","doi-asserted-by":"crossref","first-page":"17919","DOI":"10.1038\/s41598-021-97482-2","article-title":"Circulating EGFL7 distinguishes between IUGR and PE: An observational case-control study","volume":"11","author":"Massimiani","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0275","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2018.12.004","article-title":"Increased circulating levels of epidermal growth factor-like domain 7 in pregnant women affected by preeclampsia","volume":"207","author":"Massimiani","year":"2019","journal-title":"Translational Research"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0280","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1093\/nar\/gkr572","article-title":"ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif","volume":"39","author":"Morikawa","year":"2011","journal-title":"Nucleic Acids Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108764_bib438","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/jcb.27681","article-title":"Extracellular matrix (ECM) stiffness and degradation as cancer drivers","volume":"120","author":"Najafi","year":"2019","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0285","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1182\/blood-2010-03-274860","article-title":"Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7","volume":"116","author":"Nichol","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2040-2384-2-9","article-title":"EGFL7 meets miRNA-126: An angiogenesis alliance","volume":"2","author":"Nikolic","year":"2010","journal-title":"Journal of Angiogenesis Research"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0295","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2011-11-394882","article-title":"EGFL7 ligates alphavbeta3 integrin to enhance vessel formation","volume":"121","author":"Nikolic","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0300","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"23","key":"10.1016\/j.pharmthera.2024.108764_bb0305","doi-asserted-by":"crossref","first-page":"E4641","DOI":"10.1073\/pnas.1703142114","article-title":"Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia","volume":"114","author":"Papaioannou","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0310","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nature02416","article-title":"The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation","volume":"428","author":"Parker","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0315","doi-asserted-by":"crossref","first-page":"8656","DOI":"10.1074\/jbc.M110.105718","article-title":"Calcium as a crucial cofactor for low density lipoprotein receptor folding in the endoplasmic reticulum","volume":"285","author":"Pena","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0320","doi-asserted-by":"crossref","first-page":"24017","DOI":"10.1074\/jbc.M116.731331","article-title":"Endothelial cell activation is regulated by epidermal growth factor-like domain 7 (Egfl7) during inflammation","volume":"291","author":"Pinte","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0325","article-title":"EGF repeats of epidermal growth factor-like domain 7 promote endothelial cell activation and tumor escape from the immune system","volume":"47","author":"Pinte","year":"2022","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0330","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.stemcr.2019.04.022","article-title":"EGFL7 mediates BMP9-induced sprouting angiogenesis of endothelial cells derived from human embryonic stem cells","volume":"12","author":"Richter","year":"2019","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0335","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/bloodadvances.2019001002","article-title":"The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models","volume":"4","author":"Salama","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0340","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1242\/dev.002576","article-title":"EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution","volume":"134","author":"Schmidt","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0345","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ncb1896","article-title":"Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural stem cell renewal","volume":"11","author":"Schmidt","year":"2009","journal-title":"Nature Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108764_bb0350","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10456-019-09691-z","article-title":"Vessel co-option in glioblastoma: Emerging insights and opportunities","volume":"23","author":"Seano","year":"2020","journal-title":"Angiogenesis"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0355","doi-asserted-by":"crossref","first-page":"19642","DOI":"10.1016\/S0021-9258(18)41823-6","article-title":"How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X","volume":"267","author":"Selander-Sunnerhagen","year":"1992","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0360","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1093\/emboj\/cdg549","article-title":"VE-statin, an endothelial repressor of smooth muscle cell migration","volume":"22","author":"Soncin","year":"2003","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0365","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4149\/neo_2018_180310N167","article-title":"EGFL7 silencing inactivates the Notch signaling pathway; enhancing cell apoptosis and suppressing cell proliferation in human cutaneous melanoma","volume":"66","author":"Tang","year":"2019","journal-title":"Neoplasma"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0370","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1002\/cam4.2375","article-title":"Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer","volume":"8","author":"Tucker","year":"2019","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0375","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14728222.2018.1535595","article-title":"EGFL7 - a potential therapeutic target for multiple sclerosis?","volume":"22","author":"Uphaus","year":"2018","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0380","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1111\/febs.14680","article-title":"MAGP-1 and fibronectin control EGFL7 functions by driving its deposition into distinct endothelial extracellular matrix locations","volume":"285","author":"Villain","year":"2018","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0385","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1634\/theoncologist.2017-0690","article-title":"Randomized phase II trial of Parsatuzumab (anti-EGFL7) or placebo in combination with carboplatin, paclitaxel, and bevacizumab for first-line nonsquamous non-small cell lung Cancer","volume":"23","author":"Von Pawel","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0390","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1021\/acschembio.8b00291","article-title":"Calcium-mediated Allostery of the EGF fold","volume":"13","author":"Wang","year":"2018","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0395","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2016.10.009","article-title":"EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma","volume":"384","author":"Wang","year":"2017","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0400","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cac2.12092","article-title":"Proteomics identifies EGF-like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor-positive glioma","volume":"40","author":"Wang","year":"2020","journal-title":"Cancer Commun (Lond.)"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0405","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41419-022-05354-y","article-title":"EGFL7 drives the evolution of resistance to EGFR inhibitors in lung cancer by activating NOTCH signaling","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0410","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1110\/ps.041207005","article-title":"Evolution of distinct EGF domains with specific functions","volume":"14","author":"Wouters","year":"2005","journal-title":"Protein Science"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0415","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/hep.23197","article-title":"Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma","volume":"50","author":"Wu","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12943-019-0998-y","article-title":"A positive feed-forward loop between LncRNA-URRCC and EGFL7\/P-AKT\/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma","volume":"18","author":"Zhai","year":"2019","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0425","doi-asserted-by":"crossref","first-page":"1157287","DOI":"10.3389\/fneur.2023.1157287","article-title":"Microglia in the context of multiple sclerosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-022-09839-4","article-title":"Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer","volume":"26","author":"Zhang","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.pharmthera.2024.108764_bb0435","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40470","article-title":"LncEGFL7OS regulates human angiogenesis by interacting with MAX at the EGFL7\/miR-126 locus","volume":"8","author":"Zhou","year":"2019","journal-title":"Elife"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:07:06Z","timestamp":1777493226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":90,"alternative-id":["S0163725824001840"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108764","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFL7: An emerging biomarker with great therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108764"}}